Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
29 april, 22:00
29 april, 22:00
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
PR Newswire
GAITHERSBURG, Md., April 29, 2026
GAITHERSBURG, Md. , April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of the event and replay are as follows:
Conference call details: | |
Date: | May 6, 2026 |
Time: | 8:30 a.m. ET |
URL to register phone: | |
Dial-in number: | (888) 880-3330 (U.S.) or |
(+1) (646) 357-8766 (International) | |
Webcast: |
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, May 6, 2026, until 11:59 p.m. ET, May 13, 2026 |
Dial-in number: | (800) 770-2030 (U.S.) or |
(+1) (609) 800-9909 (International) | |
Passcode: | 1309751# |
Webcast: | ir.novavax.com/events , until June 6, 2026 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M ® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Jim Kelly
844-668-2829
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com

SOURCE Novavax, Inc.

29 april, 22:00
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
PR Newswire
GAITHERSBURG, Md., April 29, 2026
GAITHERSBURG, Md. , April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of the event and replay are as follows:
Conference call details: | |
Date: | May 6, 2026 |
Time: | 8:30 a.m. ET |
URL to register phone: | |
Dial-in number: | (888) 880-3330 (U.S.) or |
(+1) (646) 357-8766 (International) | |
Webcast: |
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, May 6, 2026, until 11:59 p.m. ET, May 13, 2026 |
Dial-in number: | (800) 770-2030 (U.S.) or |
(+1) (609) 800-9909 (International) | |
Passcode: | 1309751# |
Webcast: | ir.novavax.com/events , until June 6, 2026 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M ® adjuvant and protein-based nanoparticles. The Company's growth strategy focuses on maximizing the impact of its cutting-edge technology by forging strategic partnerships for its Matrix-M adjuvant and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Jim Kelly
844-668-2829
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com

SOURCE Novavax, Inc.

Analys
Rapporter
Lyxsektorn
Svensk ekonomi
Analys
Rapporter
Lyxsektorn
Svensk ekonomi
1 DAG %
Senast
OMX Stockholm 30
−1,21%
(vid stängning)
Svedbergs
Idag, 15:00
Svedbergs: Köpläge i svackan?
Getinge
Idag, 14:58
Miljardärerna tankar Getinge-aktier
OMX Stockholm 30
1 DAG %
Senast
3 073,69